Format

Send to

Choose Destination
Prim Care Diabetes. 2014 Jul;8(2):111-7. doi: 10.1016/j.pcd.2013.07.005. Epub 2013 Aug 14.

Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.

Author information

1
Centro de Atención Integral en Diabetes, Endocrinología y Metabolismo, Chacabuco, Province of Buenos Aires, Argentina.
2
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
3
Medicine Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
4
Department of Endocrinology, First Moscow State Medical University, Moscow, Russia.
5
Novo Nordisk Region International Operations A/S, Zurich, Switzerland. Electronic address: jwch@novonordisk.com.
6
Endocrine Service at the University Hospital "Dr José E González" School of Medicine UANL, Monterrey, Mexico.

Abstract

AIMS:

Biphasic insulin aspart 30 allows fewer daily injections versus basal-bolus insulin regimens, which may improve adherence and treatment outcome. This sub-analysis of the observational A1chieve study assessed clinical safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes previously receiving basal-bolus insulin regimens.

METHODS:

A1chieve was an international, open-label, 24-week study in people with type 2 diabetes starting/switching to biphasic insulin aspart 30, insulin detemir or insulin aspart. This sub-analysis assessed patients switching from insulin glargine- or neutral protamine Hagedorn insulin-based basal-bolus insulin regimens to biphasic insulin aspart 30.

RESULTS:

1024 patients were included. At 24 weeks, glycated haemoglobin and fasting plasma glucose were significantly reduced from baseline in both cohorts (all p<0.001). The proportion reporting any hypoglycaemia, major hypoglycaemia or nocturnal hypoglycaemia was significantly reduced after 24 weeks (all p<0.05). No serious adverse drug reactions were reported. Both cohorts had significantly improved health-related quality of life (HRQoL; p<0.001).

CONCLUSIONS:

24 weeks after switching from basal-bolus insulin regimens to biphasic insulin aspart 30, glycaemic control and HRQoL were significantly improved, and hypoglycaemia was significantly reduced. This suggests that people with type 2 diabetes inadequately controlled on basal-bolus insulin regimens can consider biphasic insulin aspart 30.

KEYWORDS:

A(1)chieve; Basal-bolus insulin regimen; Biphasic insulin aspart; Type 2 diabetes

PMID:
23953707
DOI:
10.1016/j.pcd.2013.07.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center